Mycobacterium tuberculosis drug resistance in HIV patients in Baixada Santista, São Paulo, Brazil;Resistência do Mycobacterium tuberculosis às drogas em pacientes HIV+ em cinco municípios da Baixada Santista, São Paulo, Brasil

Cadernos de Saude Publica

Volumn 23, Issue 5, 2007, Pages 1051-1059

  Rozman, Luciana Martins ^a   Santo, Augusto Hasiak ^a   Rozman, Mauro Abrahão ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b CATHOLIC UNIVERSITY OF SANTOS   (Brazil)

Author keywords

Drug resistance; HIV; Tuberculosis

Indexed keywords

EID: 34248355210     PISSN: 0102311X     EISSN: 16784464     Source Type: Journal    
DOI: 10.1590/s0102-311x2007000500007     Document Type: Article

References (48)

1. a Ed. Brasília: Fundação Nacional de Saúde; 2002.
2. World Health Organization. Tuberculosis. Geneva: World Health Organization; 2002. (Fact Sheet, 104).
3. Narain JP, Raviglione MC, Kochi A. HIV-associated tuberculosis in developing countries; epidemiology and strategies for prevention. Tuber Lung Dis 1992; 73:311-21.
4. Catwell MF, Snider DE, Cauthen GM, Onorato IM. Epidemiology of tuberculosis in the United States, 1985 through 1992. JAMA 1994; 272:535-9.
5. García-García MR, Valdespino-Gómez JL, García-Sancho MC, Salcedo-Álvarez RA, Zacarias F, Sepulveda-Amor JS. Epidemiology of AIDS and tuberculosis. Bull Pan Am Health Organ 1995; 29:37-58.
6. World Health Organization. Global tuberculosis control: WHO report. Geneva: World Health Organization; 2003.
7. Rossetti MLR, Valim ARM, Silva MSN, Rodrigues VS. Tuberculose resistente: revisão molecular. Rev Saúde Pública 2002; 36:525-32.
8. Natal S, Valente JG, Sánchez AR, Penna MLR. Resistência a isoniazida e rifampicina e história de tratamento anterior para tuberculose. Cad Saúde Pública 2003; 19:1277-81.
9. Centro de Vigilância Epidemiológica, Secretaria de Estado da Saúde. A tuberculose no Estado de São Paulo. http://www.cve.saude. sp.gov.br (acessado em 24/Out/2006).
10. Schwoebel V, Dicludt B, Binoist A, Haeghebaert S, Torrea G, Vincent V, et al. Multidrug resistant tuberculosis in France 1992-4: two case-control studies. BMJ 1998; 317:630-1.
11. Snider DE, Roper WL. The new tuberculosis. N Engl J Med 1992; 32:106-10.
12. Vareldzis BP, Grosset J, Kantos I, Crofton J, Laszlo A, Felten M, et al. Drug-resistant tuberculosis: laboratory issues. Tuber Lung Dis 1994; 75:1-7.
13. Hosmer JR, Lemeshow S. Applied logistic regression. New York: John Wiley and Sons; 1989.
14. Pinto WP. Tuberculose e resistência a drogas em pacientes atendidos em um centro de referência para síndrome da imunodeficiência adquirida em São Paulo - Brasil [Tese de Doutorado]. São Paulo: Faculdade de Medicina, Universidade de São Paulo; 1998.
15. Fandinho FCO, Kritski AL, Hofer C, Conde Jr. H, Ferreira RMC, Silva MG, et al. Drug resistance patterns among hospitalized tuberculous patients in Rio de Janeiro, Brazil, 1993-1994. Mem Inst Oswaldo Cruz 1999; 94:543-7.
16. Toman K. Tuberculosis, detección de casos y quimioterapia. Preguntas y respuestas. Washington DC: Organización Panamericana de la Salud; 1980. (Publicación Científica, 392).
17. Barreto AM, Martins FM. Estudo da resistência primária no Brasil no período de 1986 a 1988. Bol Campanha Nac Tuberc 1988; 2:21-5.
18. Silva EAM, Sato DN, Telles MAS, Martins MC, Palaci M, Ueki SYM. Perfil de resistência de Mycobacterium tuberculosis no Estado de São Paulo, 1986 a 1990. Rev Inst Adolfo Lutz 1992; 52:37-40.
19. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. Clin Infect Dis 1997; 24 Suppl 1:121-30.
20. Espinal MA, Laserson K, Camacho M, Fuscheng Z, Kim SJ, Tladi RE, et al. Determinants of drug-resistant tuberculosis: analysis of 11 countries. Int J Tuberc Lung Dis 2001; 5:885-6.
21. Sandman L, Schluger NW, Davidow AL, Bonk S. Risk factors for rifampin-monoresistant tuberculosis: a case-control study. Am J Respir Crit Care Med 1999; 159:468-72.
22. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York city, 1993-1994. Clin Infect Dis 1997; 25:1465-7.
23. Dye C, Watt, CJ, Bleed D. Low access to a highly effective therapy: a challenge for international tuberculosis control. Bull World Health Organ 2002; 80:437-44.
24. Machado ES, Cruz ML, Souza MJ, Ribeiro S, Silva MG, Giordani ML, et al. Drug-resistant tuberculosis in HIV+ and HIV- patients. In: International Conference on AIDS, 10; International Conference on STD, 5. Abstracts. Yokohama: International AIDS Society; 1994. p. 168.
25. Almeida-da-Silva PE, Osório M, Reinhardt MC, Fonseca LS, Delladostin AO. Drug resistance of strains of Mycobacterium tuberculosis isolated in Brazil. Microbes Infect 2001; 3:1111-3.
26. Baptista IMFD, Oelemann MC, Opromolla DVA, Suffys PN. Drug resistance and genotypes of strains of Mycobacterium tuberculosis isolated from human immunodeficiency virus-infected and noninfected tuberculosis patients in Bauru, São Paulo, Brazil. Mem Inst Oswaldo Cruz 2002; 97:1147-52.
27. March F, Garriga X, Rodríguez P, Moreno C, Garrigó M, Coll P, et al. Acquired drug resistance in Mycobacterium tuberculosis isolates recovered from compliant patients with human immunodeficiency virus - associated tuberculosis. Clin Infect Dis 1997; 25:1044-7.
28. Bradford WZ, Martin JN, Reingold AL, Schecter GF, Hopewell PC, Small PM. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet 1996; 348:928-31.
29. Small PM, Shafer RW, Hopewell PC. Exogenus reinfection with drug-resistant Mycobaterium tuberculosis in patients with advanced HIV infection. N Engl J Med 1993; 328:1137-44.
30. Lee BL, Safrin S. Interactions and toxicities of drugs used in patients with AIDS. Clin Infect Dis 1992; 14:773-9.
31. Peloquim CA, MacPhee AA, Berning SE. Malabsorption of antimycobacterial medications. N Engl J Med 1993; 329:1122-3.
32. Nunn P, Elliott AM, McAdam KP. Impact of human immunodeficiency virus on tuberculosis on developing countries. Thorax 1994; 49:511-8.
33. Ackah A, Coulibaly D, Digbeu H, Diallo K, Vetter K, Coulibaly I, et al. Response to treatment, mortality, and CD4 lymphocyte counts in HIV-infected persons with tuberculosis in Abidjan, Côte d'Ivoire. Lancet 1995; 345:607-10.
34. Di Perri G, Vento S, Cruciani M, Micciolo R, Concia E, Bassetti D. Tuberculosis and HIV infection. N Engl J Med 1991; 325:1882-3.
35. Antonucci G, Girardi E, Raviglione M, Ippolito G. Risk factors for tuberculosis in HIV persons. A prospective cohort study. JAMA 1995; 274:143-8.
36. Murray J, Sonnenberg P, Shearer S, Godfrey-Faussett P. Drug-resistant pulmonary tuberculosis in a cohort of southern African goldminers with a high prevalence of HIV infection. S Afr Med J 2000; 90:381-6.
37. Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059-64.
38. Santoro-Lopes G, Pinho AMF, Harrison LH, Schechter M. Reduced risk of tuberculosis among Brazilian patients with advanced human immunodeficiency virus infection treated with highly active antiretroviral therapy. Clin Infect Dis 2002; 34:543-6.
39. World Health Organization/International Union Against Tuberculosis and Lung Disease. Global project on anti-tuberculous drug resistance surveillance. Report 2: prevalence and trends. Geneva: World Health Organization; 2000.
40. Frieden TR, Sterling T, Mendez AP, Kilburn JO, Cauthen GM, Dooley SW. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med 1993; 328:521-6.
41. Salomon N, Perlman DC, DePalo VA, Kolokathis A, Wilets I. Drug-resistant tuberculosis: factors associated with rise in resistance in an HIV-infected urban population. Mt Sinai J Med 1994; 61:341-8.
42. Gordin FM, Nelson ET, Matts JP, Cohn PL, Ernest J, Benator D, et al. The impact of human immunodeficiency virus infection on drug- resistant tuberculosis. Am J Respir Crit Care Med 1996; 154:1478-83.
43. Liu Z, Shilkret KL, Finelli L. Epidemiology of drugresistant tuberculosis in New Jersey from 1991 to 1995. Int J Epidemiol 1998; 27:121-6.
44. Wilkinson D, Pillay M, Davies G, Sturn A. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics. Trans R Soc Trop Med Hyg 1996; 90:692-5.
45. Boudville I, Wong S, Snodgrass I. Drug resistant tuberculosis in Singapore. Ann Acad Med Singapore 1997; 26:549-56.
46. Barroso EC, Mota RMS, Santos RO, Sousa ALO, Barroso JB, Rodrigues JLN. Fatores de risco para tuberculose multirresistente adquirida. J Pneumol 2003; 29:89-97.
47. Kochi A, Vareldzis B, Styblo K. Multidrug-resistant tuberculosis and its control. Res Microbiol 1993; 144:104-10.
48. Barroso EC, Rodrigues JLN, Pinheiro VGF, Campelo CL. Prevalência da tuberculose multirresistente no Estado do Ceará, 1990-1999. J Pneumol 2001; 27:310-4.